A phase II study of saracatinib (AZD0530), a Src inhibitor, administered orally daily to patients with advanced thymic malignancies
- 1 July 2015
- journal article
- Published by Elsevier in Lung Cancer
- Vol. 89 (1) , 57-60
Abstract
No abstract availableKeywords
Funding Information
- AstraZeneca
This publication has 19 references indexed in Scilit:
- Thymic Malignancies*Journal of the National Comprehensive Cancer Network, 2010
- Thymomas: Review of Current Clinical PracticeThe Annals of Thoracic Surgery, 2009
- Src family kinases, key regulators of signal transductionOncogene, 2004
- Octreotide Alone or With Prednisone in Patients With Advanced Thymoma and Thymic Carcinoma: An Eastern Cooperative Oncology Group Phase II TrialJournal of Clinical Oncology, 2004
- Malignant thymoma in the United States: Demographic patterns in incidence and associations with subsequent malignanciesInternational Journal of Cancer, 2003
- Immunohistochemical study of tyrosine phosphorylation signaling in Hassa N's corpuscles of the human thymusActa Histochemica, 1999
- Treatment of Invasive Thymoma With Single-Agent IfosfamideJournal of Clinical Oncology, 1999
- Cisplatin plus doxorubicin plus cyclophosphamide in metastatic or recurrent thymoma: final results of an intergroup trial. The Eastern Cooperative Oncology Group, Southwest Oncology Group, and Southeastern Cancer Study Group.Journal of Clinical Oncology, 1994
- Chemotherapy for invasive thymoma. A 13-year experienceCancer, 1991
- Characterization of the protein apparently responsible for the elevated tyrosine protein kinase activity in LSTRA cells.Molecular and Cellular Biology, 1984